TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants born before week 32 of gestation.~* Preterm infant who is less than 33 weeks postmenstrual age at the time of randomization.~* Preterm infant who is appropriate for gestational age (AGA) or small for gestational age (SGA) at birth.~* Preterm infant who is receiving food enterally (bottle or gavage tube) at a level of at least 100 ml/kg/day at randomization.~* Preterm infant whose enteral feeding consists of only infant formula or only pasteurized breast milk at the time of inclusion, and who are expected to remain on only infant formula for 4 weeks, or only pasteurized breast milk for at least 2 weeks following treatment initiation.~* Preterm infant who is expected not to receive any fresh breast milk for 4 weeks following treatment initiation.~* Informed consent is obtained.~Exclusion Criteria:~* Expected stay in the hospital is less than 4 weeks from the first dose of study drug.~* Criteria to ensure no disease or treatment affecting growth or development, e.g. brain disease, necrotizing enterocolitis.~* Enrolled in another concurrent clinical intervention study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Weeks
- Healthy Volunteers: f

Study Arms:
- rhBSSL (Type: EXPERIMENTAL): rhBSSL (recombinant human bile-salt-stimulated lipase)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy~Exclusion Criteria~* Has abnormal liver test parameters, e.g., AST or ALT \> 10 times upper limit of normal~* Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion~* Has life expectancy of less than five days

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Eye Movements and Reading Disabilities

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. Age 7 to 13 (Must be in at least 2nd grade, but not higher than 8th grade) 2. Complete ophthalmic examination performed by a pediatric ophthalmologist and orthoptist.~  3. All ocular structures must be within normal limits. 4. Best corrected visual acuity must be equal to or better than 20/30 in each eye.~  5. Group 1:~ 1. Children with a reading disability must be given the diagnosis by a clinical educational specialist, educational psychologist or neuro-behavioral psychologist.~ 2. Children with a reading disability may not have any ophthalmic anomaly determined by testing as described above. This includes but is not limited to amblyopia, strabismus, nystagmus, or any organic disease.~     6. Group 2~  a. Eye movement disorder confirmed by testing by a pediatric ophthalmologist and/or orthoptist b. All other ocular structures must be within normal limits (including visual acuity).~  7. Group 3:~ 1. No evidence of reading disability, attention deficit disorder or ocular anomaly, including eye muscle or movement disorder as specified above.~     Exclusion Criteria:~* 1. Myopia more than - 6.00 diopters (spherical equivalent) in either eye. 2. Hyperopia more than + 6.00 diopters (spherical equivalent) in either eye. 3. History of vision therapy or orthoptic treatment 4. Any ocular anomaly with the exception of eye movement disorder for group 2.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- Children with reading disabilities (Type: None): Children diagnosed with reading disabilities (age 7 to 13).
- Children with eye movement disorders (Type: None): Children diagnosed with eye movement disorders (age 7 to 13).
- Control Group (Type: None): Children with normal reading ability and normal eye movements (age 7 to 13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women called back from a screening mammography by either FFDM or tomosynthesis with soft tissue abnormalities including masses, asymmetries, focal asymmetries or architectural distortion with or without calcifications. Patients will be questioned regarding the possibility of pregnancy and will need a negative pregnancy test prior the study intervention.~Exclusion Criteria:~* Age \<30 years old~* Screening mammography with only calcifications abnormalities~* Male patients~* Pregnant or lactating patients~* Patients with any allergy to iodinated contrast~* Patients with eGFR \< 45~* Patients that may be treated with radioactive iodine

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contrast-Enhanced Spectral Mammography (CESM) (Type: None): Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75 years~2. Hepatocellular carcinoma confirmed by pathology~3. No macroscopic tumor thrombus vascular invasion and distant metastasis~4. R0 resection（clean resection margin both macroscopically and microscopically）~5. MVI confirmed by pathology~6. ECOG 0-1~7. Child-Pugh stage A~8. WBC \> 3×10E9/L；HB \> 90 G/L；PLT \> 50×10E9/L~9. ALT，AST not exceeding 5 times of the upper limit of normal value；CRE，TBIL not exceeding 1.5 times of the upper limit of normal value~Exclusion Criteria:~1. Tumor rupture or invading to adjacent organs~2. Patients who underwent liver transplantation~3. Past history of or simultaneously receiving other anti-cancer therapy (such as TACE, chemotherapy, radiotherapy and others）and immune cell infusion therapy~4. Uncontrolled cardiovascular and cerebrovascular diseases~5. History of gastrointestinal bleeding within 6 months~6. Active infection other than HBV, HCV~7. Postoperative complications, not suitable to take Sorafenib (such as long term use of drainage due to bile leakage, poor wound healing and others)~8. Confirmed liver cancer recurrence or metastasis within 4 weeks after hepatectomy~9. Poor compliance, cannot adhere to regular follow up~10. Diagnosed with other original malignant tumors other than HCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
- Control (Type: NO_INTERVENTION): No use of Sorafenib (Nexavar). Regular treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Phone Application Versus Handheld Device for Fetal Vibroacoustic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant patients at 32 to 42 weeks gestation who are already undergoing fetal heart rate monitoring in the hospital setting at Hutzel Hospital in Detroit, Michigan in triage, the antepartum floor, or on labor and delivery.~Exclusion Criteria:~* Clinically unstable patients, patient who have been on magnesium sulfate or had opioid administration within the last 4 hours, fetuses with intrauterine growth restriction, patients contracting more than 3 times in 10 minutes, and twin pregnancies or higher order multiples.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Fetal Acoustic Stimulator (Type: ACTIVE_COMPARATOR): Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
- Mobile Phone Application (Type: EXPERIMENTAL): Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Course on Stress Reduction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients have a history of moderate to severe chronic pain~Exclusion Criteria:~* non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- YOGA patients (Type: EXPERIMENTAL): Patients assessed for chronic pain at our Pain Management Centre

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of prostate cancer~* Evidence of PSA progression despite castrate levels of testosterone (\<50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRH-a)~* Patients with non-metastatic or stable metastatic disease~* Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) \[cut off levels will be \> 20 U/L for enzyme linked immunosorbent (ELISA) assay and \> 100 ng/ml for immunoradiometric (IRMA) assay\]~Exclusion Criteria:~* Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel)~* First line treatment with antiandrogen in monotherapy~* Visceral metastasis~* Previous or concomitant treatment with a somatostatin analogue

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): None
- Arm B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject provides informed consent~* Subject is \>18 years of age~* Subject is deemed competent for making medical decisions~* Subject is scheduled to undergo pleuroscopy as part of their standard care for pre-operative clinical staging of malignant pleural mesothelioma~* A negative pregnancy test is required in women of child-bearing potential, as standard of care.~* Subject is mentally capable of understanding study procedures.~Exclusion Criteria~Study subject has any disease or condition that interferes with safe completion of the study including:~* Platelet count \< 50K, coagulopathy defined as an International Normalized Ratio (INR) \> 1.5~* Anticoagulants such as clopidogrel, heparin, low-molecular weight heparin, warfarin or other novel anticoagulants have not been held for the standard time period published~* Hemodynamic instability with systolic blood pressure \<90 mmHg or heart rate \> 120 beats/min, unless deemed to be stable with these values by the surgical or interventional pulmonary attending physicians.~* Hypoxemia with pulse oximetry values \<88% or partial pressure of oxygen in arterial blood (PaO2) \< 60 on baseline oxygen requirements.~* Concurrent participation in another study involving investigational drugs or investigational medical devices~* Absence of or limited access to the pleural space during medical pleuroscopy.~* Inability to read and understand the necessary study documents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryotherapy (Type: EXPERIMENTAL): Cryospray and biopsies
- Control (Type: OTHER): Biopsies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 21-100 years of age~* Patients presenting for surgical repair of a thoracoabdominal aneurysm~* Insertion of a CSF spinal drain for clinically indicated reason~Exclusion Criteria:~* Patients with pre-existing delirium~* Inability to speak and understand English~* Severe hearing impairment, resulting in inability to converse~* Pregnancy. Pregnancy status will be assessed using a serum pregnancy test during preoperative evaluation as part of the standard of care.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Open repair of thoracoabdominal aneurysms (Type: NO_INTERVENTION): These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
- Stent graft repair of thoracoabdominal aneurysms isoflurane (Type: ACTIVE_COMPARATOR): These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
- Stent graft repair of thoracoabdominal aneurysms propofol (Type: ACTIVE_COMPARATOR): These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treating Tuberculosis Wasting With a High-protein Supplement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with TB~* Aged 18 years and above~* BMI\<20~Exclusion Criteria:~* Pregnancy~* Commencement of treatment ≥30 days prior to inclusion~* Decreased kidney function~* Missing informed consent~* Mentally ill/disabled patients unable to comply with the treatment/intervention regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
- Intervention (Type: EXPERIMENTAL): Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology (ASA) physical status 1 or 2~* Male or female subjects ages 14 to 18 years old at time of procedure~* Patients who undergo an ACL repair using the hamstring autograft at The Children's Hospital of Philadelphia~* Parental/guardian permission (informed consent) and if appropriate, child assent~Exclusion Criteria:~* Parents/patients refusal to the placement of a femoral and/or sciatic nerve block~* Contraindications to femoral and/or sciatic nerve block:~  1. Infection~ 2. Neurologic deficits, including motor and/or sensory deficit of the femoral and sciatic nerves.~* Patients' inability to participate in pain scoring because of developmental delay.~* Performance of an all-epiphyseal ACL repair.~* Allergy to any of the medications used in the study.~* Presence of a coagulopathy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Males Single shot peripheral nerve block (Type: ACTIVE_COMPARATOR): a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
- Females Single shot peripheral nerve block (Type: ACTIVE_COMPARATOR): a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
- Males Continuous peripheral neural infusion (Type: ACTIVE_COMPARATOR): The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
- Females Continuous peripheral neural infusion (Type: ACTIVE_COMPARATOR): The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 and less than 75 years~* Male~* Unilateral inguinal hernia scheduled for elective open repair~Exclusion Criteria:~* Incarcerated hernia or urgent procedure~* Reoperation (recurrent hernia)~* Contraindication to regional anesthesia such as:~* Coagulopathy~* Infection at the site of needle insertion~* Pre-existing chronic pain (at any site) requiring treatment~* Contraindication to any study medication (local anesthetic or ketamine)~* History of significant Axis I psychiatric disease (major depressive disorder,bipolar disorder, schizophrenia, etc.)~* Significant hepatic (ALT or AST \> 2 times normal) or renal (serum creatinine \> 2 mg/dl) impairment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine (Type: ACTIVE_COMPARATOR): Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
- Lidocaine/ketamine (Type: ACTIVE_COMPARATOR): Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
- Placebo (Type: PLACEBO_COMPARATOR): General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues